Literature DB >> 8335676

Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.

P C Gokhale1, R J Barapatre, S H Advani, N A Kshirsagar, S K Pandya.   

Abstract

The case of a female patient with acute lymphoblastic leukaemia and chronic disseminated candidiasis, who was refractory to 1.8 g conventional amphotericin B therapy, is reported. She experienced severe amphotericin-B-related side-effects in spite of pretreatment, but was subsequently successfully treated with 3 g of a small unilamellar liposome formulation of amphotericin B prepared from soya phosphatidylcholine and cholesterol in a 7:3 molar ratio at our institute. The patient experienced minimal side-effects with this preparation, although no pretreatment was given. Liposomal amphotericin B prepared in our institute appears to be a safe and effective therapy for systemic fungal infections. However, large controlled studies are required to determine more precisely the potential of liposomal amphotericin B in the treatment of severe systemic fungal infection.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8335676     DOI： 10.1007/bf01372718

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  9 in total

Review 1.  Fungal infections in the immunocompromised host.

Authors:  C Hawkins; D Armstrong
Journal:  Clin Haematol       Date:  1984-10

2.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

3.  Hepatic candidiasis: an increasing problem in immunocompromised patients.

Authors:  E Haron; R Feld; P Tuffnell; B Patterson; R Hasselback; A Matlow
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

4.  Pharmacokinetics and tolerance of liposomal amphotericin B in patients.

Authors:  P C Gokhale; R J Barapatre; S H Advani; N A Kshirsagar; S K Pandya
Journal:  J Antimicrob Chemother       Date:  1993-07       Impact factor: 5.790

5.  Candidiasis in cancer patients.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

6.  Preclinical & pharmaceutical testing of liposomal amphotericin B.

Authors:  P C Gokhale; R N Kotwani; S Y Dange; N A Kshirsagar; S K Pandya
Journal:  Indian J Med Res       Date:  1993-04       Impact factor: 2.375

7.  Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.

Authors:  O Ringdén; F Meunier; J Tollemar; P Ricci; S Tura; E Kuse; M A Viviani; N C Gorin; J Klastersky; P Fenaux
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

8.  Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B.

Authors:  A Shirkhoda; G Lopez-Berestein; J M Holbert; M A Luna
Journal:  Radiology       Date:  1986-05       Impact factor: 11.105

9.  Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections.

Authors:  J P Sculier; A Coune; F Meunier; C Brassinne; C Laduron; C Hollaert; N Collette; C Heymans; J Klastersky
Journal:  Eur J Cancer Clin Oncol       Date:  1988-03
  9 in total
  6 in total

Review 1.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

2.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

3.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

Review 4.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006

Review 5.  Candida infections and their prevention.

Authors:  M Anaul Kabir; Zulfiqar Ahmad
Journal:  ISRN Prev Med       Date:  2012-11-04

6.  Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical.

Authors:  Arnaldo Lopes Colombo; Thaís Guimarães; Luis Fernando Aranha Camargo; Rosana Richtmann; Flavio de Queiroz-Telles; Mauro José Costa Salles; Clóvis Arns da Cunha; Maria Aparecida Shikanai Yasuda; Maria Luiza Moretti; Marcio Nucci
Journal:  Braz J Infect Dis       Date:  2013-05-18       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.